title: Intratumoral therapy of glioblastoma multiforme using genetically engineered transferrin for drug delivery.
abstract: Glioblastoma multiforme (GBM) is the most common and lethal primary brain tumor with median survival of only 12 to 15 months under the current standard of care. To both increase tumor specificity and decrease nonspecific side effects, recent experimental strategies in the treatment of GBM have focused on targeting cell surface receptors, including the transferrin (Tf) receptor, that are overexpressed in many cancers. A major limitation of Tf-based therapeutics is the short association of Tf within the cell to deliver its payload. We previously developed two mutant Tf molecules, K206E/R632A Tf and K206E/K534A Tf, in which iron is locked into each of the two homologous lobes. Relative to wild-type Tf, we showed enhanced delivery of diphtheria toxin (DT) from these mutants to a monolayer culture of HeLa cells. Here, we extend the application of our Tf mutants to the treatment of GBM. In vitro treatment of Tf mutants to a monolayer culture of glioma cells showed enhanced cellular association as well as enhanced delivery of conjugated DT. Treatment of GBM xenografts with mutant Tf-conjugated DT resulted in pronounced regression in vivo, indicating their potential use as drug carriers.
authors.affiliation: Department of Bioengineering, University of California, Los Angeles, CA 90095, USA.
authors.forename: Dennis J
authors.initials: DJ
authors.lastname: Yoon
authors.forename: Byron H
authors.initials: BH
authors.lastname: Kwan
authors.forename: Felix C
authors.initials: FC
authors.lastname: Chao
authors.forename: Theodore P
authors.initials: TP
authors.lastname: Nicolaides
authors.forename: Joanna J
authors.initials: JJ
authors.lastname: Phillips
authors.forename: Gretchen Y
authors.initials: GY
authors.lastname: Lam
authors.forename: Anne B
authors.initials: AB
authors.lastname: Mason
authors.forename: William A
authors.initials: WA
authors.lastname: Weiss
authors.forename: Daniel T
authors.initials: DT
authors.lastname: Kamei
mesh_terms: D000818:Animals; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D045744:Cell Line, Tumor; D006224:Cricetinae; D004167:Diphtheria Toxin / Q000008:administration & dosage* / Q000493:pharmacokinetics; D016503:Drug Delivery Systems / Q000379:methods*; D005260:Female; D005818:Genetic Engineering / Q000379:methods; D005909:Glioblastoma / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D000922:Immunotoxins / Q000008:administration & dosage* / Q000235:genetics / Q000493:pharmacokinetics; D051379:Mice; D008819:Mice, Nude; D016297:Mutagenesis, Site-Directed; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000235:genetics / Q000493:pharmacokinetics; D014168:Transferrin / Q000008:administration & dosage* / Q000235:genetics / Q000493:pharmacokinetics; D023041:Xenograft Model Antitumor Assays
chemical_list: D004167:Diphtheria Toxin; D000922:Immunotoxins; D011994:Recombinant Proteins; D014168:Transferrin
references.citation: J Neurooncol. 2003 Oct;65(1):3-13
references.pmid: 14649881
references.citation: J Biol Chem. 1988 Jan 25;263(3):1295-300
references.pmid: 3257214
references.citation: Semin Immunol. 2008 Oct;20(5):267-75
references.pmid: 18539480
references.citation: Neurosurg Focus. 2006 Apr 15;20(4):E5
references.pmid: 16709036
references.citation: Protein Expr Purif. 2001 Oct;23(1):142-50
references.pmid: 11570856
references.citation: J Clin Neurosci. 2004 Nov;11(8):807-18
references.pmid: 15519855
references.citation: Cancer Res. 1994 Dec 15;54(24):6387-94
references.pmid: 7987833
references.citation: Biochemistry. 1998 Jun 2;37(22):7919-28
references.pmid: 9609685
references.citation: J Control Release. 2009 Feb 10;133(3):178-84
references.pmid: 18992290
references.citation: Biochemistry. 1999 Jul 27;38(30):9704-11
references.pmid: 10423249
references.citation: Nature. 1984 Nov 8-14;312(5990):162-3
references.pmid: 6095085
references.citation: Biochemistry. 1993 Sep 14;32(36):9398-406
references.pmid: 8369310
references.citation: J Biol Inorg Chem. 2009 Jun;14(5):771-81
references.pmid: 19290554
references.citation: Curr Treat Options Neurol. 2009 Jul;11(4):297-305
references.pmid: 19523355
references.citation: J Clin Pathol. 1983 May;36(5):539-45
references.pmid: 6302135
references.citation: Biochemistry. 2002 Jul 30;41(30):9448-54
references.pmid: 12135367
references.citation: J Clin Oncol. 2002 Mar 1;20(5):1389-97
references.pmid: 11870184
references.citation: Oncogene. 2005 Jan 27;24(5):829-37
references.pmid: 15580296
references.citation: Nat Med. 1997 Dec;3(12):1362-8
references.pmid: 9396606
references.citation: Agressologie. 1980;21(1):27-30
references.pmid: 6263123
references.citation: Pharmacol Rev. 2002 Dec;54(4):561-87
references.pmid: 12429868
references.citation: J Biol Chem. 1983 Apr 25;258(8):4715-24
references.pmid: 6300098
references.citation: Blood. 1990 May 15;75(10):1903-19
references.pmid: 2186818
references.citation: Neurotherapeutics. 2009 Jul;6(3):539-46
references.pmid: 19560743
references.citation: Int J Biochem Cell Biol. 1999 Oct;31(10):1111-37
references.pmid: 10582342
references.citation: CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
references.pmid: 18287387
references.citation: Proc Natl Acad Sci U S A. 1994 Mar 15;91(6):2076-80
references.pmid: 8134351
references.citation: J Neurosurg. 1994 Mar;80(3):520-6
references.pmid: 8113865
references.citation: N Engl J Med. 2008 Jul 31;359(5):492-507
references.pmid: 18669428
references.citation: Eur J Clin Invest. 2002 Mar;32 Suppl 1:61-9
references.pmid: 11886434
references.citation: J Natl Cancer Inst. 1990 Jul 4;82(13):1107-12
references.pmid: 2359136
references.citation: Tohoku J Exp Med. 1987 Nov;153(3):239-43
references.pmid: 3433281
references.citation: Biochemistry. 2003 Apr 8;42(13):3701-7
references.pmid: 12667060
references.citation: N Engl J Med. 2005 Mar 10;352(10):987-96
references.pmid: 15758009
references.citation: J Control Release. 2007 Feb 26;117(3):403-12
references.pmid: 17239470